HRSA Debates Adding Rare MLD to Newborn Disease Screening Panel
Published Date: 8/14/2025
Notice
Summary
HRSA is thinking about adding Metachromatic Leukodystrophy (MLD), a serious condition, to the list of diseases newborns get screened for. This means babies could be tested early without families paying extra, helping catch MLD sooner and possibly save lives. HRSA wants your thoughts before making a final call, so speak up soon!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
If Added, Screening Covered Without Cost-Sharing
If HRSA adds Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP), newborn screening for MLD that is included in HRSA-supported comprehensive guidelines must be covered by non-grandfathered health plans without cost-sharing (no co-payment or co-insurance).
Supports Early Newborn Screening for MLD
HRSA is considering recommending MLD be added to the RUSP to support screening during the newborn period and is specifically asking for evidence about the potential benefit of early screening and the availability of effective treatments for MLD.
State Screening Capacity Will Be Considered
HRSA will consider the ability of state newborn screening programs to screen for MLD when deciding whether to recommend adding MLD to the RUSP, so state program capacity is part of the decision process.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16871, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Rural Maternity and Obstetrics Management Strategies Program Data Collection, OMB No. 0915-0394-Revision
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
2026-16396, National Newborn Screening Stakeholder Workgroup
HRSA provides funding to support a national center for newborn screening systems known as the National Center for Newborn Screening Systems Excellence (NBS Excel). In fiscal year 2026, supplemental funding is being provided to NBS Excel to establish a national newborn screening stakeholder workgroup. This workgroup will be a pathway for conditions to be considered and recommended for inclusion in the Recommended Uniform Screening Panel (RUSP) and to discuss national- level issues related to newborn screening. Membership will include representatives from a wide range of newborn screening experts and stakeholders. The award recipient will convene the workgroup and develop findings, reports, and recommendations for HRSA's review and consideration. HRSA will then make recommendations to the Secretary of Health and Human Services, who has final decision-making authority on updates to the RUSP.
2026-16227, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Transforming Pediatrics for Early Childhood Program Performance Measures
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
2026-16054, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Organ Procurement and Transplantation Network Board of Directors and Committee Member Applications and Forms
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
2026-15596, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; National Health Service Corps Scholar/Students to Service Travel Worksheet, OMB No. 0906-0087-Revision
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
2026-15633, Notice Regarding 340B Rebate Model Pilot Program
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternatives, HRSA is announcing this Pilot, which will implement a rebate approach for a limited set of drugs, and which builds on established and successful rebate programs. ---------------------------------------------------------------------------
Previous / Next Documents
Previous: 2025-15431, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings this fall to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide which science projects get funding. If you’re a researcher waiting on grant news, these dates in September and October 2025 are key moments for your proposals.
Next: 2025-15433, Notice With Request for Comment: Consideration of Adding Duchenne Muscular Dystrophy to the Recommended Uniform Screening Panel
HRSA is thinking about adding Duchenne Muscular Dystrophy (DMD) to the list of diseases newborns get screened for right after birth. This change would help babies with DMD get diagnosed early, and health plans would cover the screening without extra costs. HRSA wants your thoughts on how useful early screening is, if states can do it, and if good treatments are ready.